WO2001015736A3 - Interferon-beta conjugates - Google Patents

Interferon-beta conjugates Download PDF

Info

Publication number
WO2001015736A3
WO2001015736A3 PCT/DK2000/000471 DK0000471W WO0115736A3 WO 2001015736 A3 WO2001015736 A3 WO 2001015736A3 DK 0000471 W DK0000471 W DK 0000471W WO 0115736 A3 WO0115736 A3 WO 0115736A3
Authority
WO
WIPO (PCT)
Prior art keywords
interferon
polypeptide
amino acid
moiety
polypeptide moiety
Prior art date
Application number
PCT/DK2000/000471
Other languages
French (fr)
Other versions
WO2001015736A2 (en
Inventor
Anders Hjelholt Pedersen
Hans Thalsgaard Schambye
Kim Vilbour Andersen
Claus Bornaes
Poul Baad Rasmussen
Original Assignee
Maxygen Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2001520147A priority Critical patent/JP2003527090A/en
Priority to IL14758100A priority patent/IL147581A0/en
Priority to HU0302674A priority patent/HUP0302674A2/en
Priority to KR1020027002608A priority patent/KR20020034181A/en
Application filed by Maxygen Aps filed Critical Maxygen Aps
Priority to SK294-2002A priority patent/SK2942002A3/en
Priority to EP00954404A priority patent/EP1328295A2/en
Priority to BR0013638-7A priority patent/BR0013638A/en
Priority to CA002380760A priority patent/CA2380760A1/en
Priority to AU66870/00A priority patent/AU6687000A/en
Priority to MXPA02001969A priority patent/MXPA02001969A/en
Publication of WO2001015736A2 publication Critical patent/WO2001015736A2/en
Priority to AU42310/01A priority patent/AU4231001A/en
Priority to PCT/DK2001/000182 priority patent/WO2001068141A2/en
Priority to NO20020929A priority patent/NO20020929L/en
Publication of WO2001015736A3 publication Critical patent/WO2001015736A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A conjugate exhibiting interferon β activity and comprising at least one first non-polypeptide moiety covalently attached to an interferon β polypeptide, the amino acid sequence of which differs from that of wildtype human interferon β in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy.
PCT/DK2000/000471 1999-08-27 2000-08-25 Interferon-beta conjugates WO2001015736A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EP00954404A EP1328295A2 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
HU0302674A HUP0302674A2 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
KR1020027002608A KR20020034181A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
CA002380760A CA2380760A1 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
SK294-2002A SK2942002A3 (en) 1999-08-27 2000-08-25 A conjugate exhibiting interferon beta, a nucleotide sequence, an expressing vector, a host cell containing such a nucleotide sequence, method for the preparation thereof, pharmaceutical composition containing the same and its use
IL14758100A IL147581A0 (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
BR0013638-7A BR0013638A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
JP2001520147A JP2003527090A (en) 1999-08-27 2000-08-25 Novel interferon beta-like molecule
AU66870/00A AU6687000A (en) 1999-08-27 2000-08-25 New interferon beta-like molecules
MXPA02001969A MXPA02001969A (en) 1999-08-27 2000-08-25 New interferon betalike molecules.
AU42310/01A AU4231001A (en) 2000-03-17 2001-03-16 Dispersions of polypeptide conjugates
PCT/DK2001/000182 WO2001068141A2 (en) 2000-03-17 2001-03-16 Dispersions of polypeptide conjugates
NO20020929A NO20020929L (en) 1999-08-27 2002-02-26 Novel interferon beta-like molecules

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DKPA199901197 1999-08-27
DKPA199901197 1999-08-27
US16078299P 1999-10-21 1999-10-21
US60/160,782 1999-10-21
DKPA199901691 1999-11-26
DKPA199901691 1999-11-26
DKPA200000194 2000-02-07
DKPA200000194 2000-02-07
DKPA200000363 2000-03-07
DKPA200000363 2000-03-07
DKPA200000642 2000-04-14
DKPA200000642 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001015736A2 WO2001015736A2 (en) 2001-03-08
WO2001015736A3 true WO2001015736A3 (en) 2003-05-22

Family

ID=27545189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2000/000471 WO2001015736A2 (en) 1999-08-27 2000-08-25 Interferon-beta conjugates

Country Status (14)

Country Link
EP (1) EP1328295A2 (en)
JP (1) JP2003527090A (en)
KR (1) KR20020034181A (en)
CN (1) CN1501815A (en)
AU (1) AU6687000A (en)
BR (1) BR0013638A (en)
CA (1) CA2380760A1 (en)
CZ (1) CZ2002521A3 (en)
HU (1) HUP0302674A2 (en)
IL (1) IL147581A0 (en)
MX (1) MXPA02001969A (en)
NO (1) NO20020929L (en)
SK (1) SK2942002A3 (en)
WO (1) WO2001015736A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104043112B (en) * 2014-07-01 2016-03-30 哈药集团生物工程有限公司 A kind of ointment pharmaceutical composition containing recombinanthumaninterferonα-2b (pseudomonas)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2630278T3 (en) * 1998-10-16 2017-08-21 Biogen Ma Inc. Interferon beta-1a polymer conjugates and uses thereof
ES2265693T3 (en) 1998-10-16 2007-02-16 Biogen Idec Ma Inc. FUSION PROTEINS WITH INTERFERON-BETA AND USES.
US7431921B2 (en) 2000-04-14 2008-10-07 Maxygen Aps Interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
WO2002036628A2 (en) * 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
YU48703A (en) 2001-02-27 2006-05-25 Maxygen Aps New interferon beta-like molecules
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
KR100511749B1 (en) * 2001-11-06 2005-09-02 선바이오(주) Modified interferon-beta, and chemically modified conjugates thereof
EA009783B1 (en) 2002-01-18 2008-04-28 Байоджен Айдек Ма Инк. Polyalkylene glycolhaving a moiety for conjugation of a biologically active compound
AU2003254641A1 (en) * 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
PL219741B1 (en) * 2002-12-26 2015-07-31 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
CN101880326B (en) * 2003-08-25 2018-02-16 东丽株式会社 Interferon beta compound
EP1674113A1 (en) * 2004-12-22 2006-06-28 F. Hoffmann-La Roche Ag Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CN101506232A (en) * 2006-08-08 2009-08-12 诺瓦提斯公司 Recombinant interferon-beta with enhanced biological activity
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
CL2008002399A1 (en) * 2007-08-16 2009-01-02 Pharmaessentia Corp Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c.
KR20230079520A (en) 2014-11-06 2023-06-07 파마에센시아 코퍼레이션 Dosage Regimen for PEGylated Interferon
US11236141B2 (en) * 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
WO1995027502A1 (en) * 1994-04-12 1995-10-19 Research Development Foundation Method of treating auto-immune diseases using type one interferons
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1998035026A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000023114A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Polymer conjugates of interferon beta- 1a and their uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2524586B2 (en) * 1985-06-26 1996-08-14 シタス コーポレイション Solubilization of proteins for pharmaceutical compositions utilizing polymer conjugation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4917888A (en) * 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
EP0370205A2 (en) * 1988-09-29 1990-05-30 Kyowa Hakko Kogyo Co., Ltd. Glycosylated polypeptides
WO1995027502A1 (en) * 1994-04-12 1995-10-19 Research Development Foundation Method of treating auto-immune diseases using type one interferons
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
WO1998035026A1 (en) * 1997-02-06 1998-08-13 Novo Nordisk A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
WO1999003887A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
WO2000023114A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Polymer conjugates of interferon beta- 1a and their uses

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104043112B (en) * 2014-07-01 2016-03-30 哈药集团生物工程有限公司 A kind of ointment pharmaceutical composition containing recombinanthumaninterferonα-2b (pseudomonas)

Also Published As

Publication number Publication date
HUP0302674A2 (en) 2003-11-28
JP2003527090A (en) 2003-09-16
BR0013638A (en) 2002-05-14
EP1328295A2 (en) 2003-07-23
MXPA02001969A (en) 2003-07-21
NO20020929D0 (en) 2002-02-26
CA2380760A1 (en) 2001-03-08
NO20020929L (en) 2002-04-25
WO2001015736A2 (en) 2001-03-08
SK2942002A3 (en) 2002-08-06
KR20020034181A (en) 2002-05-08
AU6687000A (en) 2001-03-26
IL147581A0 (en) 2002-08-14
CZ2002521A3 (en) 2002-05-15
CN1501815A (en) 2004-06-02

Similar Documents

Publication Publication Date Title
WO2001036001A3 (en) Interferon gamma conjugates
WO2001015736A3 (en) Interferon-beta conjugates
EP2080771A3 (en) New interferon beta-like molecules
WO2001051510A3 (en) G-csf conjugates
WO2002055532A3 (en) Variant growth hormone molecules conjugated with macromolecular compounds
EP2112161A3 (en) Peptides that lower blood glucose levels
EP2016950A8 (en) Pharmaceutical composition comprising an exendin-4 peptide
HK1030768A1 (en) Cyclic amino acids and derivatives thereof useful as pharmaceutical agents.
CA2063886A1 (en) Polyethylene protein conjugates
WO1997025052A3 (en) Compositions comprising pvp having an average molecular weight in the range of 3,000 to 14,000 daltons
EP2186902A3 (en) Medical preparations for the treatment of alpha-galactosidase a deficiency
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
CA2064689A1 (en) Stabilized protein or peptide conjugates
EP2266590A3 (en) Active agent delivery sytems and methods for protecting and administering active agents
AU6934300A (en) Tissue electroperforation for drug delivery and diagnostic sampling
HUP9800049A3 (en) Amino acid compositions and use thereof in clinical nutrition, and use of the said amino acids for preparing pharmaceutical compns. for the diminution of tnf
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO2003055916A3 (en) Adiponectin fragments and conjugates
EP2213302A3 (en) DR4 antibodies and uses thereof
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
YU32402A (en) Interferon gamma conjugates
CA2324467A1 (en) Formulations for protection of peg-interferon alpha conjugates
UA100967C2 (en) Normal;heading 1;heading 2;heading 3;POLYMER CONJUGATES OF NEUBLASTIN AND METHODS OF USING SAME
WO2003037272A3 (en) Thymosin alpha 1 peptide/polymer conjugates
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147581

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002/00337

Country of ref document: ZA

Ref document number: 200200337

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000954404

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2380760

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 66870/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2002-521

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/256/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001969

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2942002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1020027002608

Country of ref document: KR

Ref document number: 008121966

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2002 2002107676

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027002608

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-521

Country of ref document: CZ

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000954404

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-521

Country of ref document: CZ